JP5698979B2 - マクロライド系抗菌剤の調製プロセス - Google Patents

マクロライド系抗菌剤の調製プロセス Download PDF

Info

Publication number
JP5698979B2
JP5698979B2 JP2010531238A JP2010531238A JP5698979B2 JP 5698979 B2 JP5698979 B2 JP 5698979B2 JP 2010531238 A JP2010531238 A JP 2010531238A JP 2010531238 A JP2010531238 A JP 2010531238A JP 5698979 B2 JP5698979 B2 JP 5698979B2
Authority
JP
Japan
Prior art keywords
formula
compound
alkyl
heteroaryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010531238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500834A (ja
Inventor
ペレイラ，デイヴィッド，イー．
パテル，マニシュ，カンチャンブハイ
デオ，ケスハヴ
Original Assignee
センプラ ファーマシューティカルズ，インコーポレイテッド
センプラ ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センプラ ファーマシューティカルズ，インコーポレイテッド, センプラ ファーマシューティカルズ，インコーポレイテッド filed Critical センプラ ファーマシューティカルズ，インコーポレイテッド
Publication of JP2011500834A publication Critical patent/JP2011500834A/ja
Application granted granted Critical
Publication of JP5698979B2 publication Critical patent/JP5698979B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010531238A 2007-10-25 2008-10-23 マクロライド系抗菌剤の調製プロセス Active JP5698979B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98244607P 2007-10-25 2007-10-25
US60/982,446 2007-10-25
PCT/US2008/080936 WO2009055557A1 (en) 2007-10-25 2008-10-23 Process for the preparation of macrolide antibacterial agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014227753A Division JP6167095B2 (ja) 2007-10-25 2014-11-10 マクロライド系抗菌剤の調製プロセス

Publications (2)

Publication Number Publication Date
JP2011500834A JP2011500834A (ja) 2011-01-06
JP5698979B2 true JP5698979B2 (ja) 2015-04-08

Family

ID=40580003

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010531238A Active JP5698979B2 (ja) 2007-10-25 2008-10-23 マクロライド系抗菌剤の調製プロセス
JP2014227753A Active JP6167095B2 (ja) 2007-10-25 2014-11-10 マクロライド系抗菌剤の調製プロセス
JP2017124117A Active JP6845099B2 (ja) 2007-10-25 2017-06-26 マクロライド系抗菌剤の調製プロセス
JP2019092242A Pending JP2019147827A (ja) 2007-10-25 2019-05-15 マクロライド系抗菌剤の調製プロセス

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014227753A Active JP6167095B2 (ja) 2007-10-25 2014-11-10 マクロライド系抗菌剤の調製プロセス
JP2017124117A Active JP6845099B2 (ja) 2007-10-25 2017-06-26 マクロライド系抗菌剤の調製プロセス
JP2019092242A Pending JP2019147827A (ja) 2007-10-25 2019-05-15 マクロライド系抗菌剤の調製プロセス

Country Status (9)

Country Link
US (3) US9453042B2 (enExample)
EP (1) EP2214484A4 (enExample)
JP (4) JP5698979B2 (enExample)
CN (2) CN101917850B (enExample)
AU (2) AU2008316830B2 (enExample)
CA (1) CA2703475A1 (enExample)
HK (1) HK1226411A1 (enExample)
IL (1) IL205254A (enExample)
WO (1) WO2009055557A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
CN107854477A (zh) 2008-10-24 2018-03-30 森普拉制药公司 使用含三唑的大环内酯治疗抗性疾病的方法
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
HRP20160168T1 (hr) * 2010-03-22 2016-03-25 Cempra Pharmaceuticals Inc Kristalne forme makrolida i njihova uporaba
BR112012029586A2 (pt) 2010-05-20 2016-08-02 Cempra Pharmaceuticals Inc processos para preparar macrolídeos e cetolídeos e intermediários dos mesmos
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
WO2014152326A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
AU2014233240B2 (en) * 2013-03-15 2018-08-09 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
EP4095146A1 (en) 2013-04-04 2022-11-30 President And Fellows Of Harvard College Macrolides and methods of their preparation and use
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
JP2017531663A (ja) * 2014-10-08 2017-10-26 プレジデント アンド フェローズ オブ ハーバード カレッジ １４員ケトライドならびにそれらの調製および使用の方法
CN107207418A (zh) * 2015-02-06 2017-09-26 森普拉制药公司 4‑叠氮基丁胺和制备方法
PE20180219A1 (es) * 2015-03-06 2018-01-31 Cempra Pharmaceuticals Inc Procesos para preparar fluorocetolidos
WO2016154591A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
CN106518939B (zh) * 2015-09-14 2019-12-31 江苏奥赛康药业有限公司 一种制备Solithromycin化合物的方法
CN106554381A (zh) * 2015-09-25 2017-04-05 苏州鹏旭医药科技有限公司 酮内酯类抗生素中间体及其制备方法和应用
CN105348341B (zh) * 2015-12-04 2018-01-09 浙江京新药业股份有限公司 一种制备索利霉素的方法
CN105503976B (zh) * 2015-12-04 2018-02-06 浙江京新药业股份有限公司 一种索利霉素中间体
EP3190122A1 (en) 2016-01-08 2017-07-12 LEK Pharmaceuticals d.d. A novel synthetic pathway towards solithromycin and purification thereof
TW201811811A (zh) * 2016-09-02 2018-04-01 森普拉製藥公司 製備氟酮內酯之方法

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1354753A (en) 1919-02-11 1920-10-05 E M Lannes Portable building
US2180006A (en) 1936-09-09 1939-11-14 Eastman Kodak Co Process for the separation and refining of amines
GB891817A (en) 1959-04-07 1962-03-21 Upjohn Co Improvements in or relating to injectable tetracyclic preparations
US3843787A (en) 1969-01-15 1974-10-22 Pierrel Spa Water soluble derivative of erythromycin
US3668282A (en) 1970-05-08 1972-06-06 Stauffer Chemical Co Stabilized mixture employing n-(beta-0,0-dialkyldithiophosphoryl) aryl sulfonamides
EP0012521B1 (en) 1978-12-11 1983-03-23 Bexford Limited Vesicular recording materials and process for their production
SE458505B (sv) 1979-07-10 1989-04-10 Lepetit Spa Anvaendningen av rifamycin sv och salter daerav foer framstaellning av en beredning foer behandling av reumatoid artrit samt vissa av salterna och deras framstaellning
US4331803A (en) * 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
JPS59104326A (ja) 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
JPS59175414A (ja) 1983-03-23 1984-10-04 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
US4742049A (en) * 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
HU198913B (en) 1987-09-03 1989-12-28 Pliva Pharm & Chem Works Process for producing 10-dihydro-10-deoxo-11-aza-erythronolide a-derivatives and pharmaceutical compositions containing them as active components
BE1001869A3 (fr) 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
IL99995A (en) * 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5985844A (en) * 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
TW271400B (enExample) 1992-07-30 1996-03-01 Pfizer
FR2697524B1 (fr) * 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) * 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
JPH07126172A (ja) 1993-11-05 1995-05-16 Genichiro Soma Ｌｐｓを含む抗ｍｒｓａ剤及び動物用抗ｍｒｓａ剤
FR2718450B1 (fr) * 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) * 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US5834428A (en) * 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) * 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) * 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) * 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) * 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
DE69733439T2 (de) * 1996-09-04 2006-05-04 Abbott Laboratories, Abbott Park 6-o-Substituierte Ketoliden mit antibakteriellen Wirkung
KR20000069431A (ko) 1996-12-13 2000-11-25 피터 지. 스트링거 Ｐｓａ의 효소 활성 억제제
KR20010013660A (ko) 1997-06-11 2001-02-26 실버스타인 아써 에이. 9-옥심 에리트로마이신 유도체
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
US6407074B1 (en) * 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
HN1998000074A (es) 1997-06-11 1999-01-08 Pfizer Prod Inc Derivados de macrolidos c-4 sustituidos
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
AU749623B2 (en) 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
FR2777282B1 (fr) * 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6020521A (en) * 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
FR2785612A1 (fr) * 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2786188B1 (fr) * 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
KR100317907B1 (ko) 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
ATE344269T1 (de) * 1998-12-10 2006-11-15 Pfizer Prod Inc Carbamat und carbazat ketolid antibiotika
DK1147121T3 (da) 1999-01-27 2004-04-13 Pfizer Prod Inc Ketolidantibiotika
CA2292359C (en) 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
FR2789392B1 (fr) 1999-02-04 2001-10-05 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
AR023264A1 (es) 1999-04-08 2002-09-04 Hokuriku Pharmaceutical Derivados de eritromicina
JP2000351794A (ja) 1999-04-08 2000-12-19 Hokuriku Seiyaku Co Ltd エリスロマイシン誘導体
AU775637B2 (en) * 1999-04-16 2004-08-12 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6399582B1 (en) 1999-04-16 2002-06-04 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6420535B1 (en) * 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) * 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
WO2001010878A1 (fr) 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
AU3337900A (en) 1999-08-09 2001-03-05 Eric Au An apparatus for treating wastewater
US6096922A (en) 1999-11-01 2000-08-01 Air Products And Chemicals, Inc. Process for the synthesis of dialkyl, diaryl, and arylalkyl aminosulfur trifluorides
KR100336447B1 (ko) * 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
US20020009507A1 (en) 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2001261694A (ja) * 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
DE60122791T2 (de) 2000-03-15 2007-10-04 Hanmi Pharm. Co., Ltd. Verfahren zur Herstellung von Clarythromycin mit nicht pharmazeutischer Qualität
NZ523693A (en) 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20020115621A1 (en) * 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
FR2821747B1 (fr) 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Suspension de telithromycine a gout masque
ES2261735T3 (es) * 2001-05-18 2006-11-16 Chiron Corporation Sistema para la administracion de una formulacion de tobramicina.
FR2826274B1 (fr) 2001-06-21 2003-09-26 Aventis Pharma Sa Formulation pharmaceutique au gout masque et son procede de preparation
WO2003004509A2 (en) 2001-07-03 2003-01-16 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
EP1478404A1 (en) 2002-02-22 2004-11-24 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
US7375234B2 (en) * 2002-05-30 2008-05-20 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
EP1553954A4 (en) 2002-06-17 2009-12-23 Epigenesis Pharmaceuticals Llc DIHYDRATE DEHYDROEPIANDROSTERONE AND METHOD FOR THE TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE LUNG DISEASE, COMPOSITIONS THEREOF
CN100577681C (zh) 2002-07-08 2010-01-06 葛兰素伊斯特拉齐瓦基森塔萨格勒布公司 用于治疗炎性疾病和病症的新化合物、组合物和方法
US20040013737A1 (en) 2002-07-19 2004-01-22 Philippe Becourt Taste masked oral composition of telithromycin
US7091196B2 (en) * 2002-09-26 2006-08-15 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
ITMI20022292A1 (it) * 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
US7332476B2 (en) * 2003-04-25 2008-02-19 Novartis Ag Pyridyl substituted ketolide antibiotics
EP1618120A2 (en) * 2003-04-25 2006-01-25 Chiron Corporation Novel ketolide derivatives
EP1628989B1 (en) 2003-05-13 2006-12-20 Glaxo Group Limited Novel 14 and 15 membered-ring compounds
WO2005007143A2 (en) * 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Use of makrolides and ketolides for the treatment of tuberculosis
US7457520B2 (en) * 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
GB0402578D0 (en) 2004-02-05 2004-03-10 Cambridge Theranostics Ltd Methods of treatment of atherosclerosis
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
ATE373009T1 (de) 2004-04-28 2007-09-15 Alembic Ltd Verfahren zur vorbereitung von telithromycin
AU2005240849B2 (en) 2004-05-06 2008-10-23 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Ester linked macrolides useful for the treatment of microbial infections
WO2006080954A1 (en) 2004-07-28 2006-08-03 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
US20060076536A1 (en) 2004-09-29 2006-04-13 Barshied Scott R Oxygen scavenging pharmaceutical package and methods for making same
GB0424959D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
GB0424958D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
SI1836211T1 (sl) 2004-12-21 2010-04-30 Pfizer Prod Inc Makrolidi
US20080113926A1 (en) * 2005-01-14 2008-05-15 Zrinka Ivezic 9A-Carbamoyl-Y-Aminopropyl- And 9A-Thiocabamoyl-Y-Aminopropyl-Azalides With Antimalarial Activity
EP1836212B1 (en) 2005-01-14 2011-09-07 Glaxo Group Limited Macrolide compounds containing biotin and photo-affinity group for macrolide target identification
US20080227730A1 (en) 2005-01-14 2008-09-18 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 9A-Carbamoyl and Thiocarbamoyl Azalides With Antimalarial Activity
CN104922117A (zh) 2005-03-22 2015-09-23 阿泽范药品公司 用于治疗月经前病症的β-内酰氨基链烷酸
CA2609549A1 (en) 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
WO2007008537A2 (en) 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
CA2615813C (en) 2005-07-19 2015-12-15 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
MY148124A (en) 2005-10-31 2013-02-28 Leo Pharma As Preparation of a crystalline antibiotic substance
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
US20070167382A1 (en) * 2005-11-15 2007-07-19 Nina Finkelstein Crystalline and amorphous forms of telithromycin
EP1954294A2 (en) 2005-11-23 2008-08-13 Ranbaxy Laboratories Limited Use of macrolide derivatives for treating acne
WO2007060518A2 (en) 2005-11-23 2007-05-31 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
DOP2006000268A (es) * 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
FR2897154B1 (fr) 2006-02-08 2008-03-07 Airbus France Sas Dispositif pour construire et securiser une trajectoire de vol a basse altitude destinee a etre suivie par un aeronef.
CN101045063B (zh) 2006-03-28 2011-01-26 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂
JP5126685B2 (ja) 2006-05-01 2013-01-23 大正製薬株式会社 マクロライド誘導体
WO2007143507A2 (en) 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7951905B2 (en) 2006-09-18 2011-05-31 University Of Manitoba Synthesis of carbohydrate-templated amino acids and methods of using same
US8609148B2 (en) 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
UA96964C2 (ru) 2006-12-04 2011-12-26 Астразенека Аб Соединения полициклической мочевины с антибактериальными свойствами
JP5025249B2 (ja) 2006-12-15 2012-09-12 Ｎｓｋワーナー株式会社 発進クラッチ
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
WO2009053259A1 (en) 2007-10-25 2009-04-30 Sandoz Ag Process for the production of telithromycin
US7795316B1 (en) 2007-12-19 2010-09-14 Alcon Research, Ltd. Topical ophthalmic compositions containing tobramycin and dexamethasone
US20090209547A1 (en) 2008-02-15 2009-08-20 In Jong Kim C-8 halogenated macrolides
CN107854477A (zh) 2008-10-24 2018-03-30 森普拉制药公司 使用含三唑的大环内酯治疗抗性疾病的方法
WO2010077730A2 (en) 2008-12-09 2010-07-08 Auspex Pharmaceutical, Inc Indanone inhibitors of acetylcholinesterase
US9814657B2 (en) 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
RU2582938C2 (ru) 2009-06-03 2016-04-27 АльгиФарма АС Альгинатные олигомеры для применения в преодолении множественной лекарственной устойчивости у бактерий
CA2767614C (en) 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
US9480679B2 (en) 2009-09-10 2016-11-01 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and MAC diseases
US20110119604A1 (en) 2009-11-19 2011-05-19 Clevest Solutions Inc. System and method for a configurable and extensible allocation and scheduling tool
WO2011112864A1 (en) 2010-03-10 2011-09-15 Cempra Pharmaceuticals, Inc. Parenteral formulations of macrolide antibiotics
HRP20160168T1 (hr) 2010-03-22 2016-03-25 Cempra Pharmaceuticals Inc Kristalne forme makrolida i njihova uporaba
BR112012029586A2 (pt) 2010-05-20 2016-08-02 Cempra Pharmaceuticals Inc processos para preparar macrolídeos e cetolídeos e intermediários dos mesmos
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US9260473B2 (en) 2010-07-19 2016-02-16 Virginia Commonwealth University Bivalent multifunctional ligands targeting Aβ oligomers as treatment for Alzheimer's disease
US20130164351A1 (en) 2010-08-30 2013-06-27 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2012042534A2 (en) 2010-09-28 2012-04-05 Glenmark Generics Limited Processes for the preparation of r-sitagliptin and intermediates thereof
CN103619849B (zh) 2011-03-01 2016-05-25 沃克哈特有限公司 酮内酯中间体的制备方法
WO2012162439A2 (en) 2011-05-23 2012-11-29 Cem-102 Pharmaceuticals, Inc. Compositions comprising fusidic acid and packages therefor
BR112013028813B1 (pt) 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2013059610A1 (en) 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
WO2014152326A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
AU2014233240B2 (en) 2013-03-15 2018-08-09 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
EP4095146A1 (en) 2013-04-04 2022-11-30 President And Fellows Of Harvard College Macrolides and methods of their preparation and use
WO2015123256A1 (en) 2014-02-14 2015-08-20 Cempra Pharmaceuticals, Inc. Compositions and methods for treating diabetes and liver diseases
US20170101365A1 (en) 2014-05-27 2017-04-13 Dipharma Francis S.R.L. Azidoalkylamine salts and their use as intermediates
EP3185864A4 (en) 2014-08-05 2018-03-28 Cempra Pharmaceuticals, Inc. Powder oral suspension formulations of antibacterial agents
PE20180219A1 (es) 2015-03-06 2018-01-31 Cempra Pharmaceuticals Inc Procesos para preparar fluorocetolidos
TW201811811A (zh) 2016-09-02 2018-04-01 森普拉製藥公司 製備氟酮內酯之方法

Also Published As

Publication number Publication date
CN105732745A (zh) 2016-07-06
US10131684B2 (en) 2018-11-20
JP6845099B2 (ja) 2021-03-17
AU2016203649A1 (en) 2016-06-16
JP6167095B2 (ja) 2017-07-19
AU2008316830A1 (en) 2009-04-30
JP2011500834A (ja) 2011-01-06
JP2019147827A (ja) 2019-09-05
CN101917850A (zh) 2010-12-15
IL205254A (en) 2017-09-28
AU2008316830B2 (en) 2016-03-17
CA2703475A1 (en) 2009-04-30
JP2017200943A (ja) 2017-11-09
US20100216731A1 (en) 2010-08-26
US9453042B2 (en) 2016-09-27
US20170096445A1 (en) 2017-04-06
EP2214484A4 (en) 2013-01-02
IL205254A0 (en) 2010-12-30
WO2009055557A1 (en) 2009-04-30
JP2015051994A (ja) 2015-03-19
EP2214484A1 (en) 2010-08-11
US20190241602A1 (en) 2019-08-08
HK1226411A1 (zh) 2017-09-29
CN101917850B (zh) 2016-01-13

Similar Documents

Publication Publication Date Title
JP6167095B2 (ja) マクロライド系抗菌剤の調製プロセス
JP6184319B2 (ja) マクロライド類およびケトライド類ならびにその中間体を調製するための工程
EP0638584B1 (en) 5-o-desosaminylerythronolide a derivative
DK172636B1 (en) 6-o-methylerythromycin a derivative
AU2014233240B2 (en) Convergent processes for preparing macrolide antibacterial agents
CZ303474B6 (cs) 6-O-substituovaný ketolidový derivát erythromycinu, zpusob jeho prípravy, jeho použití a farmaceutická kompozice ho obsahující
CN101074252B (zh) 11,12-环碳酸酯-阿奇霉素4＂-氨甲酸酯衍生物、制备方法及其药物组合物
JP2013537213A (ja) クラジノース環のＣ−４”をエポキシド基で修飾した９−デオキソ−９ａ−アザ−９ａ−ホモエリスロマイシンＡの新規製造方法
JP2003501439A5 (enExample)
CN108610388B (zh) 一种大环内酯的制备方法
JPH0529038B2 (enExample)
JP2906663B2 (ja) ５−０−デソサミニルエリスロノライドａ誘導体
WO2003068792A1 (fr) Procede de fabrication d'un derive d'erythromycine 'a'
CA2526732A1 (en) Q-alkyl macrolide and azalide derivatives and regioselective process for their preparation
CZ20003704A3 (cs) 15-členné laktamové ketolidy s antibakteriální účinností

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120918

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20130304

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141110

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150216

R150 Certificate of patent or registration of utility model

Ref document number: 5698979

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250